Anavex Life Sciences Corp. (AVXL)
Nasdaq · Healthcare · Biotechnology
$1.65−9.62%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $153M
- 52-week range
- $1.63 – $10.38
- 52-week change
- −81.39%
- EPS (trailing)
- −$0.14
- Next earnings
- Nov 24, 2026
Fiscal year to Sep 2025
- Net income
- −$46.4M
- Diluted EPS
- −$0.54
From the company’s annual report on SEC EDGAR.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy.
Headquarters: New York, United States · 34 employees · anavex.com